| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Set1/Ash2 histone methyltransferase complex subunit ASH2;ASH2-like protein;ASH2L;ASH2L1; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A synthesized peptide derived from human ASH2L |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-ASH2L Rabbit Monoclonal Antibody is an antibody targeting ASH2L. Common applications include WB, IHC, ICC, IF. Key specifications include host: Rabbit; clonality: Monoclonal; clone: Clone: EOB-1; isotype: Rabbit IgG; reactivity: Human,Mouse,Rat; observed MW: 25 kDa; calculated MW: 68723 MW.
Boster Bio Anti-ASH2L Rabbit Monoclonal Antibody catalog # M06129. Tested in WB, IHC, ICC/IF applications. This antibody reacts with Human, Mouse, Rat.
Key elements and design rationale
- Target: ASH2L — Set1/Ash2 histone methyltransferase complex subunit ASH2
- Antibody format: Host: Rabbit; Clonality: Monoclonal; Clone: Clone: EOB-1; Isotype: Rabbit IgG
- Species reactivity: Human,Mouse,Rat
- Molecular weight guidance: Observed: 25 kDa; Calculated: 68723 MW
Biological background
Protein function (datasheet): Component of the Set1/Ash2 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3, but not if the neighboring 'Lys-9' residue is already methylated. As part of the MLL1/MLL complex it is involved in methylation and dimethylation at 'Lys-4' of histone H3. May function as a transcriptional regulator. May play a role in hematopoiesis. .
Cellular localization (datasheet): Nucleus .
Tissue details (datasheet): Ubiquitously expressed. Predominantly expressed in adult heart and testis and fetal lung and liver, with barely detectable expression in adult lung, liver, kidney, prostate, and peripheral leukocytes. .
Research relevance and current trends
- Commonly studied in contexts related to Cancer Susceptibility,Chromatin Modifying Enzymes,Chromatin Remodeling,Epigenetics and Nuclear Signaling,Methylation,Proto-Oncogenes,Transcription.
- Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
- Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).
Common research applications
- Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
- Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
- Immunofluorescence / ICC: Visualize subcellular localization and co-localization patterns; consider fixation/permeabilization compatibility and controls.
Notes for experimental interpretation
- Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
- Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.
As a monoclonal antibody, this reagent is expected to recognize a defined epitope, which can support consistency across lots when epitope accessibility is preserved.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
